St Louis, MONCT07566585Now EnrollingIRB Ready

AML - Acute Myeloid Leukemia Clinical Trial in St Louis, MO

Access cutting-edge aml - acute myeloid leukemia treatment through this clinical trial at a research site in St Louis. Study-provided care at no cost to qualified participants.

Sponsored by BlueSphere Bio, Inc

Quick Self-Assessment

See if you qualify for this St Louis location

Preparing your pre-screening questions…

Expert Care in St Louis

Access aml - acute myeloid leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related aml - acute myeloid leukemia treatment provided free

Apply for This St Louis Location

Check if you qualify for this aml - acute myeloid leukemia clinical trial in St Louis, MO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to St Louis

    Convenient for MO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit St Louis site if eligible
  4. 4Begin participation

About This AML - Acute Myeloid Leukemia Study in St Louis

The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML). It will evaluate the safety of BSB-2002 and also determine whether it works to prevent relapse of your cancer.

Sponsor: BlueSphere Bio, Inc

Who Can Participate

Inclusion Criteria

Male or female patients, ages 18 years or older,
AML diagnosed per ELN criteria1 which has been treated with at least two lines of therapy,
which is relapsed (after previously complete remission, CR, CRh or CRi), or
refractory (failed to achieve complete remission) to the last treatment\*, \*Primary refractory patients should have received at least two cycles of induction treatment
Patients who are MRD positive by NGS for NPM1 after being MRD negative following the last treatment
HLA-A\*02:01,
Positive for NPM1 mutation type A, D, G or H (see Appendix 3)2
Adequate venous access for apheresis or agree to use of a central line for apheresis collection,
Willing and able to provide informed consent and adhere to all study requirements.

Exclusion Criteria

Leukemic blast count of \>20,000/μl. If the blast count can be maintained below the threshold with hydroxyurea, the patient would be eligible.
Patients with extramedullary only AML.
Patients that are candidates for hematopoietic stem cell transplant.
Patients that are eligible to receive an approved targeted therapy.
Treatment with other investigational agents within 5 half-lives of the planned dosing of BSB-2002 (day 1).
Subject has had hematopoietic stem cell transplant (HSCT) and has any of the following:
Is within 3 months of transplant;
Has clinically significant graft-versus-host disease requiring systemic treatment;
Has ≥ Grade 2 persistent non-hematological toxicity related to the transplant.
Other malignancy that requires treatment.
Uncontrolled bacterial, viral, or fungal infections at time of enrollment.
Active Hepatitis B or C infection.
Seropositive for Human Immunodeficiency Virus-1 or -2.
CNS involvement refractory to intrathecal chemotherapy and/or standard cranial- spinal radiation.
Subject has congestive heart failure NYHA class 3 or 4, or subject with a history of congestive heart failure NYHA class 3 or 4 in the past, unless an echocardiogram performed within 3 months prior to study entry results in a left ventricular ejection fraction that is ≥ 45%.
Renal insufficiency, with estimated creatinine clearance of \< 40 ml/min/1.73m2 by the Cockcroft-Gault equation with adjustment if the weight is ≥ 125% of ideal body weight OR inadequate renal function defined by serum creatinine \> 1.6 mg/dL
Total bilirubin \> 2x upper limit of normal (unless attributed to Gilbert's Syndrome).
AST or ALT \> 3x upper limit of normal.
Pregnant or lactating women.
Eastern Cooperative Oncology Group (ECOG) performance status \>2.
Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine or systemic steroids at any dose)
Women of childbearing potential (WOCBP) and men who are fertile and are unwilling to use an effective birth control method or abstinence for 12 months. Effective forms of birth control are listed in the Contraception section.
Any condition, in the judgement of the Investigator, that would interfere with study participation, pose a significant risk to the patient, or interfere with study data interpretation.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in St Louis?

Yes, this clinical trial (NCT07566585) has an active research site in St Louis, MO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

AML - Acute Myeloid Leukemia Treatment Options in St Louis, MO

If you're searching for aml - acute myeloid leukemia treatment options in St Louis, MO, this clinical trial (NCT07566585) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our St Louis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced aml - acute myeloid leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all aml - acute myeloid leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in St Louis, MO

See all leukemia clinical trials recruiting in St Louis — not just this study.

Browse Leukemia Trials in St Louis →

Browse More Trials by Condition

Leukemia TrialsAcute Myeloid Leukemia TrialsHeart Attack TrialsMyocardial Infarction TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in St Louis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · St Louis, MO